Prevention of sudden cardiac death - Lessons from recent controlled trials

Sergio Richter, G. Duray, Gerian Grönefeld, Carsten W. Israel, Stefan H. Hohnloser

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Sudden cardiac death (SCD), presumably because of ventricular tachyarrhythmias, remains one of the major challenges of contemporary cardiology. Major randomized controlled trials conducted in patients with coronary artery disease (CAD) with the aim of primary prevention of SCD are providing insights. Several large-scale studies have demonstrated that treatment with β-blockers, angiotensin-converting enzyme inhibitors, aldosterone antagonists, and statins results not only in a reduction in all-cause mortality but specifically also in SCD. On top of this optimized pharmacological therapy, implantable cardioverter-defibrillators (ICD) further decrease the risk of overall and SCD mortality in carefully selected patient groups. The sum of these trials indicates, however, that the benefit associated with ICD therapy is most prominent in patients with chronic stable CAD. In contrast, patients early after myocardial infarction derive less benefit from ICD treatment, presumably because of a high competing risk of non-arrhythmic cardiovascular death. Optimized pharmacological therapy, together with the ICD, can substantially improve the prognosis of high-risk CAD patients.

Original languageEnglish
Pages (from-to)625-629
Number of pages5
JournalCirculation Journal
Volume69
Issue number6
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Sudden Cardiac Death
Implantable Defibrillators
Coronary Artery Disease
Pharmacology
Mineralocorticoid Receptor Antagonists
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mortality
Primary Prevention
Cardiology
Angiotensin-Converting Enzyme Inhibitors
Tachycardia
Randomized Controlled Trials
Myocardial Infarction

Keywords

  • Coronary artery disease
  • Implantable cardioverter-defibrillator
  • Randomized controlled trials
  • Sudden cardiac death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

Prevention of sudden cardiac death - Lessons from recent controlled trials. / Richter, Sergio; Duray, G.; Grönefeld, Gerian; Israel, Carsten W.; Hohnloser, Stefan H.

In: Circulation Journal, Vol. 69, No. 6, 06.2005, p. 625-629.

Research output: Contribution to journalArticle

Richter, S, Duray, G, Grönefeld, G, Israel, CW & Hohnloser, SH 2005, 'Prevention of sudden cardiac death - Lessons from recent controlled trials', Circulation Journal, vol. 69, no. 6, pp. 625-629. https://doi.org/10.1253/circj.69.625
Richter, Sergio ; Duray, G. ; Grönefeld, Gerian ; Israel, Carsten W. ; Hohnloser, Stefan H. / Prevention of sudden cardiac death - Lessons from recent controlled trials. In: Circulation Journal. 2005 ; Vol. 69, No. 6. pp. 625-629.
@article{1dd3d792bc1741b793fdb87323bda644,
title = "Prevention of sudden cardiac death - Lessons from recent controlled trials",
abstract = "Sudden cardiac death (SCD), presumably because of ventricular tachyarrhythmias, remains one of the major challenges of contemporary cardiology. Major randomized controlled trials conducted in patients with coronary artery disease (CAD) with the aim of primary prevention of SCD are providing insights. Several large-scale studies have demonstrated that treatment with β-blockers, angiotensin-converting enzyme inhibitors, aldosterone antagonists, and statins results not only in a reduction in all-cause mortality but specifically also in SCD. On top of this optimized pharmacological therapy, implantable cardioverter-defibrillators (ICD) further decrease the risk of overall and SCD mortality in carefully selected patient groups. The sum of these trials indicates, however, that the benefit associated with ICD therapy is most prominent in patients with chronic stable CAD. In contrast, patients early after myocardial infarction derive less benefit from ICD treatment, presumably because of a high competing risk of non-arrhythmic cardiovascular death. Optimized pharmacological therapy, together with the ICD, can substantially improve the prognosis of high-risk CAD patients.",
keywords = "Coronary artery disease, Implantable cardioverter-defibrillator, Randomized controlled trials, Sudden cardiac death",
author = "Sergio Richter and G. Duray and Gerian Gr{\"o}nefeld and Israel, {Carsten W.} and Hohnloser, {Stefan H.}",
year = "2005",
month = "6",
doi = "10.1253/circj.69.625",
language = "English",
volume = "69",
pages = "625--629",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "6",

}

TY - JOUR

T1 - Prevention of sudden cardiac death - Lessons from recent controlled trials

AU - Richter, Sergio

AU - Duray, G.

AU - Grönefeld, Gerian

AU - Israel, Carsten W.

AU - Hohnloser, Stefan H.

PY - 2005/6

Y1 - 2005/6

N2 - Sudden cardiac death (SCD), presumably because of ventricular tachyarrhythmias, remains one of the major challenges of contemporary cardiology. Major randomized controlled trials conducted in patients with coronary artery disease (CAD) with the aim of primary prevention of SCD are providing insights. Several large-scale studies have demonstrated that treatment with β-blockers, angiotensin-converting enzyme inhibitors, aldosterone antagonists, and statins results not only in a reduction in all-cause mortality but specifically also in SCD. On top of this optimized pharmacological therapy, implantable cardioverter-defibrillators (ICD) further decrease the risk of overall and SCD mortality in carefully selected patient groups. The sum of these trials indicates, however, that the benefit associated with ICD therapy is most prominent in patients with chronic stable CAD. In contrast, patients early after myocardial infarction derive less benefit from ICD treatment, presumably because of a high competing risk of non-arrhythmic cardiovascular death. Optimized pharmacological therapy, together with the ICD, can substantially improve the prognosis of high-risk CAD patients.

AB - Sudden cardiac death (SCD), presumably because of ventricular tachyarrhythmias, remains one of the major challenges of contemporary cardiology. Major randomized controlled trials conducted in patients with coronary artery disease (CAD) with the aim of primary prevention of SCD are providing insights. Several large-scale studies have demonstrated that treatment with β-blockers, angiotensin-converting enzyme inhibitors, aldosterone antagonists, and statins results not only in a reduction in all-cause mortality but specifically also in SCD. On top of this optimized pharmacological therapy, implantable cardioverter-defibrillators (ICD) further decrease the risk of overall and SCD mortality in carefully selected patient groups. The sum of these trials indicates, however, that the benefit associated with ICD therapy is most prominent in patients with chronic stable CAD. In contrast, patients early after myocardial infarction derive less benefit from ICD treatment, presumably because of a high competing risk of non-arrhythmic cardiovascular death. Optimized pharmacological therapy, together with the ICD, can substantially improve the prognosis of high-risk CAD patients.

KW - Coronary artery disease

KW - Implantable cardioverter-defibrillator

KW - Randomized controlled trials

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=20444396631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444396631&partnerID=8YFLogxK

U2 - 10.1253/circj.69.625

DO - 10.1253/circj.69.625

M3 - Article

VL - 69

SP - 625

EP - 629

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 6

ER -